AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23881570 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (2 words once)
Number of subjects: 3
Study 22736126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 174
Study 22736126 — intervention group
Group type: COMPARATOR
Intervention: Non-nasogastric tube
Number of subjects: 174
Study 19864082 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) plus radiation therapy (RT)
Number of subjects: 206
Study 19864082 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 206
Study 18378136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation (51 Gy in 28 fractions over 5 weeks)
Number of subjects: 224
Study 18378136 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 224
Study 15653378 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 6 months
Number of subjects: 10
Study 15653378 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 10
Study 12716753 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-LIPE diet
Number of subjects: 191
Study 12716753 — intervention group
Group type: COMPARATOR
Intervention: Standard protein restriction
Number of subjects: 191
Study 10507820 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic catheter insertion
Number of subjects: 50
Study 10507820 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter insertion
Number of subjects: 50
Study 8554941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.3 g kg-1 before an evening meal
Number of subjects: 24
Study 8554941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.3 g kg-1 after an evening meal
Number of subjects: 24
Study 8554941 — intervention group
Group type: COMPARATOR
Intervention: Fasted subjects
Number of subjects: 24
Study 8554941 — intervention group
Group type: COMPARATOR
Intervention: Fed subjects
Number of subjects: 24
Study 2231825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrostimulation (CES)
Number of subjects: 0
Study 2231825 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study 6105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (low dose)
Number of subjects: 11
Study 6105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (high dose)
Number of subjects: 11
Study 6105520 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (low dose)
Number of subjects: 11
Study 6105520 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (high dose)
Number of subjects: 11
Study 6105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (intravenous infusion)
Number of subjects: 11
Study 6105520 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (intravenous infusion)
Number of subjects: 11
Study 30704694 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled Laminar Airflow (TLA)
Number of subjects: 87
Study 30704694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 29134299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 34
Study 29134299 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 34
Study 26603627 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message promoting dietary calcium consumption
Number of subjects: 288
Study 26603627 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message promoting calcium supplements
Number of subjects: 288
Study 26603627 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 288
Study 26603627 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 288
Study 24600218 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (details not specified)
Number of subjects: 15
Study 22972835 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 h/night; 0100‐0500 h)
Number of subjects: 27
Study 20806117 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 1715
Study 20806117 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg once daily
Number of subjects: 1715
Study 20806117 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg twice daily
Number of subjects: 1715
Study 20806117 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 20 mg once daily
Number of subjects: 1715
Study 20806117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study 17408867 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious mood condition for CM-anxiety participants
Number of subjects: 48
Study 17408867 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood condition for EM participants
Number of subjects: 48
Study 17408867 — intervention group
Group type: COMPARATOR
Intervention: Positive mood condition for CM-anxiety participants
Number of subjects: 48
Study 17408867 — intervention group
Group type: COMPARATOR
Intervention: Anxious mood condition for EM participants
Number of subjects: 48
Study 15822418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil TCI (0.08-0.1 ng/ml)
Number of subjects: 26
Study 15822418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil TCI
Number of subjects: 26
Study 15822418 — intervention group
Group type: COMPARATOR
Intervention: i.v. morphine (Bolus group)
Number of subjects: 26
Study 11875316 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 22
Study 11875316 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22
Study 11875316 — intervention group
Group type: COMPARATOR
Intervention: Control (Normotensives)
Number of subjects: 22
Study 11337713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 75 mg in 20 mL of saline solution
Number of subjects: 90
Study 11337713 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg in 20 mL of saline solution
Number of subjects: 90
Study 11337713 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 20 mL
Number of subjects: 90
Study 9672330 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 8 weeks
Number of subjects: 9
Study 8790529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter
Number of subjects: 3083
Study 8790529 — intervention group
Group type: COMPARATOR
Intervention: Standard letter
Number of subjects: 3083
Study 2742729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 36
Study 2742729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 36
Study 2742729 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 36
Study 2742729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 181258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Intralipid
Number of subjects: 8
Study 181258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous egg phospholipid
Number of subjects: 8
Study 181258 — intervention group
Group type: COMPARATOR
Intervention: Intragastric Intralipid
Number of subjects: 8
Study 30910373 — intervention group
Group type: EXPERIMENTAL
Intervention: NAE (Net Acid Excretion) measurement
Number of subjects: 978
Study 30910373 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics, body composition, laboratory values (including eGFR and serum bicarbonate level)
Number of subjects: 978
Study 30910373 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance, dietary potential renal acid load, and metabolically active medications (e.g., metformin, allopurinol, nonstatin lipid agents)
Number of subjects: 978
Study 30910373 — intervention group
Group type: EXPERIMENTAL
Intervention: Body size indicators (body surface area, body mass index, fat-free mass)
Number of subjects: 978
Study 30910373 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/ethnicity and eGFR
Number of subjects: 978
Study 28549783 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan-temozolomide-dinutuximab
Number of subjects: 35
Study 28549783 — intervention group
Group type: COMPARATOR
Intervention: irinotecan-temozolomide-temsirolimus
Number of subjects: 35
Study 25939101 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) whole-body calisthenics
Number of subjects: 26
Study 25939101 — intervention group
Group type: COMPARATOR
Intervention: Typical physical training
Number of subjects: 26
Study 22956683 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (writing down when, where, and how to increase fruit and vegetable intake)
Number of subjects: 208
Study 22956683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 208
Study 21788003 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis flap
Number of subjects: 269
Study 21788003 — intervention group
Group type: COMPARATOR
Intervention: Limberg flap
Number of subjects: 269
Study 19570486 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 0
Study 16688811 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐DCRT combined with FOLFOX4 chemotherapy
Number of subjects: 48
Study 16688811 — intervention group
Group type: COMPARATOR
Intervention: 3‐DCRT
Number of subjects: 48
Study 15196613 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with the largest effect sizes
Number of subjects: 25
Study 15196613 — intervention group
Group type: COMPARATOR
Intervention: Trials with the smallest effect sizes
Number of subjects: 25
Study 11304939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetindene 0.1% (Fenistil Nasal Spray)
Number of subjects: 100
Study 11304939 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine 0.05% solution
Number of subjects: 100
Study 9322630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 405
Study 9322630 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor with epidural analgesics
Number of subjects: 405
Study 9322630 — intervention group
Group type: COMPARATOR
Intervention: Usual care control protocol
Number of subjects: 405
Study 9322630 — intervention group
Group type: COMPARATOR
Intervention: Usual care control protocol with epidural analgesics
Number of subjects: 405
Study 8140565 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (E) 25‐50 mg per day
Number of subjects: 28
Study 8140565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of altizide 15 mg and aldactone 25 mg (A) 1 or 2 tablets per day
Number of subjects: 28
Study 10279100 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction
Number of subjects: 30
Study 10279100 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 31311674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant (75 mg orally disintegrating tablet)
Number of subjects: 1466
Study 31311674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1466
Study 27860023 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer color-matching (CCM) system based on the improved back-propagation neural network (BPNN) model
Number of subjects: 43
Study 27860023 — intervention group
Group type: COMPARATOR
Intervention: Traditional visual method
Number of subjects: 43
Study 27860023 — intervention group
Group type: EXPERIMENTAL
Intervention: Color distributions (ΔL*, Δa*, and Δb*)
Number of subjects: 43
Study 26784651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 5107
Study 26784651 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 FA (1g/day)
Number of subjects: 5107
Study 26784651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 5107
Study 25172891 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state increases in P ET , CO 2 of 5 and 10 Torr above baseline
Number of subjects: 8
Study 25172891 — intervention group
Group type: COMPARATOR
Intervention: Rebreathing-induced transient breath-by-breath increases in P ET , CO 2
Number of subjects: 8
Study 25172891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation for 1 min followed by rebreathing
Number of subjects: 8
Study 25172891 — intervention group
Group type: COMPARATOR
Intervention: Rebreathing only
Number of subjects: 8
Study 22244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 3265
Study 22244381 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis In Myocardial Infarction grade 3 flow after PCI
Number of subjects: 3265
Study 20225536 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg/puff, 2 puffs/day)
Number of subjects: 14
Study 20225536 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (250 microg/puff, 2 puffs/day)
Number of subjects: 14
Study 20225536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 14
Study 16718285 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted participants
Number of subjects: 167
Study 16718285 — intervention group
Group type: COMPARATOR
Intervention: Non-stunted participants
Number of subjects: 167
Study 16718285 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted participants with greater increases in height-for-age
Number of subjects: 167
Study 16249460 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TZD)
Number of subjects: 93
Study 12925484 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (2 microg kg(‐1) over 30 s)
Number of subjects: 60
Study 12925484 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (30 microg kg(‐1) over 30 s)
Number of subjects: 60
Study 12925484 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 12925484 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 60
Study 10678439 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (within 4 weeks)
Number of subjects: 262
Study 10678439 — intervention group
Group type: COMPARATOR
Intervention: Delayed symptom-driven revascularization
Number of subjects: 262
Study 10678439 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted revascularization of > or = 66% of vessels with significant stenosis
Number of subjects: 262
Study 8767563 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 85
Study 8767563 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg clorazepate dipotassium
Number of subjects: 85
Study 8767563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 1684196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (iv)
Number of subjects: 0
Study 1684196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (iv or oral)
Number of subjects: 0
Study 1684196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 0
Study 6356321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g four times daily
Number of subjects: 80
Study 6356321 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 200 mg three times daily and 400 mg at night
Number of subjects: 80
Study 3989877 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery of a female initiating a sexual invitation and being assertive during coitus
Number of subjects: 138
Study 3989877 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery of a male initiating a sexual invitation and being assertive during coitus
Number of subjects: 138
Study 28924075 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus 30 mg/day edoxaban
Number of subjects: 38
Study 28924075 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 38
Study 27790530 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Based Protocol (EBP)
Number of subjects: 226
Study 27790530 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 226
Study 24219512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (List A)
Number of subjects: 200
Study 24219512 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (List B)
Number of subjects: 200
Study 24219512 — intervention group
Group type: COMPARATOR
Intervention: List A
Number of subjects: 200
Study 24219512 — intervention group
Group type: COMPARATOR
Intervention: List B
Number of subjects: 200
Study 22349389 — intervention group
Group type: COMPARATOR
Intervention: Avandia (group B)
Number of subjects: 180
Study 22349389 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin combined with avandia (group C)
Number of subjects: 180
Study 20575165 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-I)
Number of subjects: 53
Study 20575165 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-II)
Number of subjects: 53
Study 20575165 — intervention group
Group type: COMPARATOR
Intervention: Standard training (ST)
Number of subjects: 53
Study 18156406 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate intake of 438 microg DFE/d for 12 weeks
Number of subjects: 60
Study 16628625 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg clevudine
Number of subjects: 98
Study 16628625 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg clevudine
Number of subjects: 98
Study 16628625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 11158463 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable flow nasal CPAP
Number of subjects: 32
Study 11158463 — intervention group
Group type: COMPARATOR
Intervention: Modified nasal cannula
Number of subjects: 32
Study 11158463 — intervention group
Group type: COMPARATOR
Intervention: CPAP prongs
Number of subjects: 32
Study 9545990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 9
Study 9545990 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 9
Study 9545990 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study 8281852 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 99
Study 8281852 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 99
Study 8281852 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 99
Study 2738757 — intervention group
Group type: EXPERIMENTAL
Intervention: Special breast cleansing before breast pumping
Number of subjects: 65
Study 2738757 — intervention group
Group type: COMPARATOR
Intervention: Control group (thorough hand washing only)
Number of subjects: 65
Study 4909360 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (administered orally for 3 days)
Number of subjects: 51
Study 4909360 — intervention group
Group type: COMPARATOR
Intervention: Placebo linctus (administered orally for 3 days)
Number of subjects: 51
Study 4909360 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 51
Study 4909360 — intervention group
Group type: COMPARATOR
Intervention: Placebo linctus
Number of subjects: 51
Study 31884682 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching for 12 months
Number of subjects: 1535
Study 31884682 — intervention group
Group type: COMPARATOR
Intervention: Usual health care and long-term care (LTC)
Number of subjects: 1535
Study 29185675 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle stretching exercises
Number of subjects: 44
Study 29185675 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 44
Study 29185675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 27186571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutaf technique
Number of subjects: 81
Study 27186571 — intervention group
Group type: COMPARATOR
Intervention: Limberg flap
Number of subjects: 81
Study 24708570 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-based physical exercise (5x10 minutes per week for 10 weeks, using kettlebells, elastic bands, and exercise balls)
Number of subjects: 200
Study 24708570 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise (5x10 minutes per week for 10 weeks, using elastic bands and body weight exercises)
Number of subjects: 200
Study 24708570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received ergonomic instructions on patient handling and use of lifting aides.
Number of subjects: 200
Study 24708570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 22417197 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS for life program (manualized individual cognitive behavioral treatment)
Number of subjects: 52
Study 22417197 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOCS‐A (observer-rated youth alliance measure)
Number of subjects: 52
Study 22417197 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-therapist alliance ratings
Number of subjects: 52
Study 20861377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administered 75 min before scanning
Number of subjects: 72
Study 20861377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administered 285 min before scanning
Number of subjects: 72
Study 20861377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 18524784 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-40
Number of subjects: 84
Study 18524784 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-50
Number of subjects: 84
Study 18524784 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-60
Number of subjects: 84
Study 15853098 — intervention group
Group type: EXPERIMENTAL
Intervention: saline solution
Number of subjects: 25
Study 15853098 — intervention group
Group type: EXPERIMENTAL
Intervention: ferric sulfate
Number of subjects: 25
Study 15853098 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 25
Study 15853098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 solution
Number of subjects: 25
Study 15853098 — intervention group
Group type: COMPARATOR
Intervention: calcium hydroxide (control group)
Number of subjects: 25
Study 12362968 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT
Number of subjects: 90